Adial Pharmaceuticals Inc
NASDAQ:ADIL

Watchlist Manager
Adial Pharmaceuticals Inc Logo
Adial Pharmaceuticals Inc
NASDAQ:ADIL
Watchlist
Price: 0.2466 USD 2.75% Market Closed
Market Cap: 5.9m USD

Adial Pharmaceuticals Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Adial Pharmaceuticals Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Adial Pharmaceuticals Inc
NASDAQ:ADIL
EPS (Diluted)
$0
CAGR 3-Years
71%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
EPS (Diluted)
$10
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
EPS (Diluted)
$2
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
EPS (Diluted)
$1
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
EPS (Diluted)
$7
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
EPS (Diluted)
$20
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
25%
No Stocks Found

Adial Pharmaceuticals Inc
Glance View

Market Cap
5.9m USD
Industry
Pharmaceuticals

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The firm is also developing adenosine analogs for the treatment of pain and other disorders through its wholly owned subsidiary, Purnovate, Inc.

ADIL Intrinsic Value
0.111 USD
Overvaluation 55%
Intrinsic Value
Price

See Also

What is Adial Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-0.4 USD

Based on the financial report for Sep 30, 2025, Adial Pharmaceuticals Inc's EPS (Diluted) amounts to -0.4 USD.

What is Adial Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
54%

Over the last year, the EPS (Diluted) growth was 84%. The average annual EPS (Diluted) growth rates for Adial Pharmaceuticals Inc have been 71% over the past three years , 54% over the past five years .

Back to Top